To conduct a cost-effectiveness analysis of currently available nucleos(t)ide antiviral treatments (lamivudine, telbivudine, entecavir, and tenofovir) for chronic hepatitis B in Canada. Methods: Markov modeling was used to project the lifetime health benefits and costs associated with the antiviral treatments. The hypothetical patient population was hepatitis B e antigen-positive chronic hepatitis B-infected patients aged 34 years. Quality-adjusted life-years were used as a measure of effectiveness. Long-term cumulative incidence of liver complications was also projected. Treatment effectiveness data were derived from the literature; meta-analysis was conducted when there was a large variance in reported effectiveness data. Costs were obtained from a cost analysis of treating chronic hepatitis B-related complications in Canada. Stochastic parameter uncertainty was examined in probabilistic sensitivity analysis by using secondorder Monte Carlo simulation. Alternative modeling assumptions were assessed in scenario analysis. One-way sensitivity analysis was used to explore each parameter's impact on the uncertainty of the results.
Introduction
In Canada, the estimated number of hepatitis B virus (HBV)-infected individuals is 5.2% in immigrants, 0.7% to 0.9% in Canadianborn individuals, and 4% in aboriginals [1, 2] . The projected seroprevalence of HBV in Canada is close to 1.26% [2] ; therefore, there are approximately 430,000 Canadians infected with HBV. With 20% to 25% mortality rate among untreated cases [2] , chronic hepatitis B (CHB) infection has severe long-term outcomes and requires complex algorithms for management. The Ontario Burden of Infectious Disease study [3] estimated that 346 deaths per year in Ontario are directly attributable to chronic HBV infection, and an increasing burden to the health system is expected because of new cases of cirrhosis, liver failure, and hepatocellular carcinoma (HCC). Although antiviral treatments for CHB do not provide a complete cure except for rare cases [2] , timely treatment can significantly prevent the progression of liver damage from HBV by slowing down or stopping the virus from reproducing. Oral nucleos(t)ide analogues (NAs) have become the preferred first-line treatment for most genotypes of hepatitis B due to relatively few adverse effects compared with those of interferons. During the past 5 years, a new generation of NAs has become available. Lamivudine (LAM) was the first oral agent to be approved for the treatment of HBV infection in Canada, and until 2006 it was the only NA available. Although it is no longer recommended by the Canadian Consensus Guidelines as the first-line choice for the treatment of high viral load CHB (HBV DNA Ͼ 2 ϫ10 7 IU/mL) because of its low genetic barrier to developing resistance [2] , it is still the most commonly prescribed NA in clinical practice in Ontario. According to a national survey, in 2009 77% of treatmentnaive patients with public funding received LAM in Ontario [4] . In contrast, the consensus guidelines recommended telbivudine (LdT) for patients with both low and high viral load; however, the use of LdT in Canada was rare (2% in 2007 and 1% in 2009), mainly because of provincial reimbursement restrictions and nonsuperiority of LdT over other agents [4] .
Entecavir (ETV) was recommended by the consensus guidelines as a first-line therapy for all patients regardless of viral load. It was considered the most potent agent available before tenofovir disoproxil fumarate (TDF) was officially licensed for hepatitis B [2] . New evidence has suggested that both TDF and ETV are the most effective therapies for CHB [5, 6] , and the recent update of the American Association for the Study of Liver Diseases (AASLD) practice guideline (2010) has recommended TDF or ETV as the first-line oral antiviral medications for CHB. From 2007 to 2009, clinical practice in Canada showed a 525% increase in TDF use and 211% increase in ETV [4] .
To date, there has been no economic evaluation studying recently available nucleos(t)ide antiviral treatments for CHB from a Canadian perspective. Therefore, this study aimed to conduct an economic evaluation of these agents in Canada, using LAM as the reference.
Methods

Overview
A cost-effectiveness analysis was conducted to evaluate LdT, TDF, and ETV compared with LAM. A Markov model was chosen as the preferred structure for the analysis because of the chronic and recursive nature of chronic infection of HBV, which requires longterm follow-up to capture the relevant clinical and economic end points. The outcome measures used in the model were life-years, quality-adjusted life-years (QALYs), and costs associated with the treatments and disease progression. The analysis took the perspective of Ontario Ministry of Health and Long Term Care; therefore, only direct medical costs associated with CHB infection were considered. The time horizon of the model was the patients' lifetime. Clinical and economic outcomes were discounted at an annual rate of 5% [7] , as this is the recommended rate by Canada's HTA agency. Microsoft Office Excel 2007 was used to conduct the analysis.
Patient population and treatment regimens
A hypothetical cohort of 1000 adult patients with the following baseline characteristics was chosen to go through the model:
• Hepatitis B e antigen (HBeAg)-positive chronic HBV infection without other coinfections and complications • 34 years of age • 72% males • Mean serum alanine transaminase (ALT) level ranging from 100 to 200 IU/L • Mean serum HBV DNA concentration ranging from 10 7 to 10 10 copies/mL • No prior treatment with anti-HBV nucleos(t)ides.
The characteristics of this patient cohort were based on efficacy trials from which key disease transition probabilities were derived. The model employed 72 yearly cycles, since 99.99% of the patient cohort has died by that time on the basis of the Ontario life table [8] .
Treatment regimens included in the model were LAM (Epivir) 100 mg daily, LdT (Sebivo) 600 mg daily, TDF (Viread) 300 mg daily, and ETV (Baraclude) 0.5 mg daily, all administered orally. For patients who developed viral resistance to their initial treatments, the model employed rescue combination therapies recommended by the Canadian and AASLD guidelines, because they are consistent with the most effective care. In the case of LAM resistance, adefovir (ADV) (Hepsera, 10 mg) or TDF was added; the same add-on therapies were also used for LdT-resistant patients; for patients resistant to TDF, LAM was added; for ETV resistance, ADV was used as the add-on therapy [2, 4, 9] .
Markov model
Chronic infection with HBV can transition through multiple pathways. The diagram of disease transition under treatment is pre-sented in Figure 1 . The patient cohort enters the model in the CHB state. While receiving antiviral therapies, patients could experience serum HBeAg seroconversion (i.e., the loss of HBeAg and the gain of anti-HBe), representing that progressive liver damage has been largely controlled but that they remain at risk of cirrhosis and HCC [10] [11] [12] [13] [14] [15] . Hepatitis B surface antigen (HBsAg) clearance could also occur, indicating a cure of CHB. It is possible to develop viral resistance on long-term nucleos(t)ide treatment. Rescue therapies were administered to patients entering the resistance state. All patients except those who have lost HBsAg remain at the risk of developing cirrhosis and HCC over the long term. However, for patients who did not seroconvert but achieved viral suppression, the risk of developing cirrhosis and HCC may be reduced. During severe disease stages including decompensated cirrhosis and HCC, a liver transplant may be indicated. All states could lead to death. Because Markov models cannot hold memory of the disease transition history, several temporary states (not all shown in Fig. 1 ) were built to enable the assignment of state-specific transition probabilities and to adjust utilities and costs.
Key modeling assumptions
1. International guidelines on the therapy of hepatitis B suggest that finite duration of treatment with NAs is a reasonable option and recommend that treatment may be stopped after HBeAg seroconversion and an additional 6 to 12 months of consolidation therapy to maximize the durability of treatment response [2, 9] . The model employed the recommended treatment strategy and 12-month consolidation therapy after the confirmed appearance of anti-HBe. 2. It was assumed that 60% of LAM-resistant and LdT-resistant patients receive ADV add-on and that 40% of these patients receive TDF add-on, according to the ratio of patients receiving these rescue therapies in clinical practice in Canada [2, 4, 9] . We did not consider alternative therapies that accounted for less than 10% in Canadian clinical practice and that were not recommended by international guidelines. 3. Hundred percent durability of HBeAg seroconversion was assumed during consolidation therapy. When off treatment, serologic durability varied across antivirals. In the case of serologic relapse, which means HBeAg seroconversion reverses and is considered a reactivation of hepatitis B [2] , reinstitution of the initial antiviral treatment was applied to patients who had not developed viral resistance [9] . (continued on next page) 4. Because of relatively poor virologic durability reported in the literature [16] , reduction in cirrhosis and HCC risk for nonseroconverters was therefore assumed to occur only in the first 5 years of antiviral treatment in the base-case analysis; in subsequent years, the risk of cirrhosis and HCC was the same as the baseline. 5. Treatment effects of rescue therapies were assumed to be the same as those of the add-on therapies, since no significant difference was found in the literature [17] , except the resistance rate, which was assumed to be zero under rescue therapies [18, 19] . 6. After patients progressed to more severe disease states (cirrhosis, decompensated cirrhosis, and HCC), transition probabilities and costs were associated with routine clinical practice in Canada [20] .
Data for treatment effectiveness
All treatment-induced transition probabilities employed in the model are shown in Table 1 . Important transition probabilities include HBeAg seroconversion and its off-treatment durability, HBsAg seroclearance, drug resistance, and the risks of cirrhosis and hepatoma.
HBeAg seroconversion
Probability of HBeAg seroconversion was assumed to be higher in the first year of treatment than in subsequent years. First year on-treatment HBeAg seroconversion probabilities were derived from a recently published Bayesian meta-analysis by Woo et al. [5] .
Starting from the second year, annual seronconversion rates were basically the same regardless of the time on treatment or the NA used [22] ; therefore, the model used a constant seroconversion probability (12%) that was equal across antivirals for the following years of treatment.
HBeAg seroconversion durability
Although some studies reported comparable off-treatment serologic durability (70%-90%) across antivirals, differences compared with LAM were reported in two head-to-head studies [ Overall, limited data exist on the off-treatment durability of HBeAg seroconversion achieved with newer NAs. We calculated the weighted average (fixed-effect meta-analysis using inverse variance method) of LAM's durability data in four studies, and adjusted the reported data of LdT and ETV to make them consistent with the relative difference across antivirals. TDF's durability was assumed to be the same as that of ETV.
HBsAg seroclearance
Recent studies estimated that baseline HBsAg clearance was 1% to 2% among asymptomatic HBsAg carriers (mostly seropositive for anti-HBe) with a mean age of 33 years [37] . A fixed-effect metaanalysis was conducted for studies that reported spontaneous HBsAg loss during long-term follow-up and derived 0.9% transition probability [37, 38] . Besides, studies showed that HBsAg clearance under NA treatments is confined to those with an active immune response to HBV, such as HBeAg-positive patients who achieve HBeAg clearance [39] . Therefore, it was assumed that all HBsAg seroclearance occurred in HBeAg seroconverters. According to the literature, NAs generally have a low rate of HBsAg loss compared with interferon [40] , and HBsAg clearance was not observed in any patient treated with LAM and LdT [5] ; therefore, we used baseline probability for LAM and LdT. A systematic review also indicated that sustained effects of antiviral treatments on HBsAg loss beyond 48 weeks off treatment have not been examined [41] . We therefore assumed that all drug-induced HBsAg seroclearance occurred only in the first year after HBeAg seroconversion; in subsequent years, HBsAg clearance rate was assumed to be the same as baseline.
Drug resistance
First-year resistance probabilities in the model were based on a meta-analysis conducted for this study and a published review of clinical trials [23, 42] . For each drug, cumulative long-term resistance probabilities were converted to an annual probability that was applied to subsequent years of antiviral treatment. Resistance to ETV is rare (Ͻ1% for 3 years of treatment) in clinical trials [25] , and no TDF resistance was observed in clinical trials [21, 43] . Longer-term follow-up, however, found that resistance to TDF and ETV occurred eventually, and in most cases it was attributed to documented nonadherence [43, 44] . It was therefore assumed that the annual resistance probability of ETV and TDF was 0.3%.
Risk for cirrhosis
It was found that HBV viral load was the strongest predictor for the development of cirrhosis, independent of serum ALT level and HBeAg status [32] . According to Iloeje's 11-year populationbased prospective cohort study, annual risks for cirrhosis are 0.42%, 0.55%, 0.93%, and 2.41% for serum HBV DNA level less than 300, 300 to 10 4 , 10 4 to 10 5 , and 10 5 to 10 6 copies/mL, respectively. Transition probabilities from CHB to cirrhosis were then calculated on the basis of mean HBV DNA levels at the end of 1 year of therapy. The probabilities were adjusted slightly to account for the difference in baseline HBV DNA levels across randomized controlled trials and different drugs' potency on viral suppression [5, 21, 24, 33] .
Risk for HCC
Because HBV is an oncogenic virus, it can cause HCC in the absence of cirrhosis [45] . In HBV carriers without cirrhosis, the risk is 0.02% to 0.03% per year in Caucasians and 0.4% to 0.6% in Asians [46] . Given that chronic HBV carriers in Ontario are mostly immigrant populations, we used baseline HCC risk data from a Korean study without adjustments. Currently established major risk factors for HCC in patients with CHB include sex, age, serum ALT concentration, HBeAg status, and serum HBV DNA level [35] . Eun et al. [34] reported that HBV DNA levels greater than 10 4 copies/mL is an especially strong predictor of HCC risk in individuals aged 30 years or older. The quantitative relationship between on-treatment HBV viral load and the risk of developing HCC, however, is not yet well established, and studies regarding HCC risk are limited to conventional interferon and LAM [47] . We calculated HCC risk on the basis of Yang et al's study [35] of a risk scoring system that takes into account the above stated risk factors, and randomized controlled trials [5, 21, 24, 33] that reported HBV DNA concentration at the end of 1-year therapy.
Other transition probabilities
Please refer to 
Drug costs and health state costs
In Ontario, LAM, ETV, TDF, and ADV are reimbursed under the Exceptional Access Program, in which the reimbursement rates are the drug benefit price if they are listed in the Ontario Drug Benefit Fomulary; otherwise, reimbursement rates are the wholesale acquisition costs of the drugs. In this analysis, when available, prices listed in Quebec's formulary [58] were used as the acquisition costs. Since LdT was not listed in either Quebec or Ontario, the wholesale acquisition cost was obtained from a local pharmacy [59] . An 8% pharmacy mark-up charge [60] and a dispensing fee of Can $4.11 (i.e., Ontario Drug Benefit program fee of Can $6.11 less a Can $2 patient co-payment) were used. Cost estimates for physician fees, test fees, procedure costs, and hospitalization were taken from a cost analysis of treating CHBrelated health conditions in Canada [20] . The costs associated with laboratory tests of creatinine and phosphate were included for all the treatments under evaluation. Annual direct medical costs (2001) for managing these CHB-related disease states were as follows: Please refer to Table 3 for drug costs and annual costs of health states. The consumer price index (health care) was used to adjust the costs to 2011 values [63] .
Health utilities
Health-related quality of life (HRQOL) scores were obtained from the study conducted by Levy et al. [65] , in which trained interview- 
Analysis of uncertainty
Probabilistic sensitivity analysis
In addition to using point estimates for input values, our disease transition model was made probabilistic to assess the simultaneous impact of parameter uncertainty on the analysis. The probability distribution for each input parameter is presented in Tables 1 to 4. Beta distributions were assumed for probability and utility values; Gamma distributions were used for cost variables; lognormal distributions were assumed for relative risk variables. Second-order Monte Carlo simulation was conducted by using 2000 trials for the probabilistic analysis. Uncertainty in the results was expressed by using cost-effectiveness acceptability curves based on the net benefit framework [66] . Willingness-to-pay (WTP) per QALY gained ranged from $0 to $200,000.
Scenario analysis of alternative model assumptions
Two scenarios were considered for parameters that are not adequately studied so far. Scenario 1 was to assume equal serologic durability (82%) across antivirals after 12 months of consolidation therapy. Scenario 2 was to assume reduced risk of developing cirrhosis and HCC sustained until the termination of antiviral therapy.
One-way sensitivity analysis
The impact of parameter uncertainty for the optimal strategy was also explored in one-way sensitivity analysis on each parameter. The analysis was based on the net monetary benefit framework and was focused on the optimal strategy (i.e., TDF) in the deterministic model. Despite the lack of an explicit WTP ware, Inc., 2011 version); the same results were generated. Second, the 10-year cumulative incidence of liver complications and undiscounted life expectancy projected by the model was compared with those from other published economic evaluations (see Discussion section). Third, the risk of HCC was compared with the original source of the HCC risk assessment under long-term LAM treatment [34] : a 4-year cumulative HCC incidence was 1.46% in the model and 1.53% (median 4.4 years) in the observational study. We can also see from the cost-effectiveness plane (Fig. 2 ) that on average, TDF generated the best results. It dominated both
Results
Model validation and calibration
Base-case analysis
LdT and ETV with lower cost and better effectiveness. The 10-year cumulative incidence of cirrhosis, decompensated cirrhosis, and HCC under LAM treatment projected by the model was 17.23%, 2.07%, and 5.20%, respectively, while under TDF treatment, the risks were significantly lower: 11.40%, 1%, and 3.05%, respectively.
One-way sensitivity analysis
One-way sensitivity analyses for TDF were conducted by varying all model parameters over their range of values. The 10 most influential parameters were selected for the Tornado diagram (Fig. 3) . The key drivers on the uncertainty of the results were found to be HBeAg seroconversion rates in the first and subsequent years under TDF, the cost of the drug, and its relapse rate. However, none of these variations changed the status of TDF being the most cost-effective treatment, except ETV's relapse rate. By using threshold analysis, we found that when ETV's probability of relapse is below 0.074, ETV is preferred over TDF as the optimal treatment strategy.
Probabilistic sensitivity analysis
The uncertainty of the cost-effectiveness results for a range of WTP thresholds is presented as cost-effectiveness acceptability curves in Figure 4 . The cost-effectiveness acceptability curves for the base-case scenario showed that TDF was the most costeffective treatment in 65% to 78% of the simulations for WTP thresholds less than Can $200,000, followed by ETV, which was the optimal strategy in 11% to 27% of the simulations. For ceiling ratios (maximum WTP per QALY) beyond Can $200,000, the probability of being the most cost-effective strategy stayed steady for all comparators. LdT was almost never the most costeffective treatment regardless of how high the ceiling ratio was set. At thresholds below Can $40,000, LAM was the optimal strategy in as much as 23.7% of the simulations.
Scatter plots provided more detailed information in individual comparisons. It was indicated that in the base-case scenario, TDF dominated LAM, LdT, and ETV in 71%, 91%, and 56% of the simulations, respectively ( Fig. 5A-C) ; ETV dominated LAM in about 28% of the simulations, and in most other cases was more costly and more effective than LAM (Fig. 5D ). The probability of ETV's incremental cost-effectiveness ratio (ICER) (compared with that of LAM) being below Can $20,000 per QALY was 54% while that of TDF was 90%.
Scenario analysis
When setting the HBeAg serologic durability rate to be the same as reference therapy and equal across antivirals, ICERs of the treatments increased. TDF still generated cost savings and dominated all other treatments. LdT was still the most costly and least effective therapy compared with ETV and TDF. When assuming a reduced risk of cirrhosis and HCC sustained until the termination of antiviral therapy, results were significantly improved: TDF's QALYs increased from 11.86 to 12.72 and cost decreased from Can $104,034 to Can $93,564. ICERs were lower for all therapies (Table 6 ).
Discussion
This study is the first Canadian economic evaluation to assess the cost-effectiveness of first-line oral NAs in the treatment of HBeAgpositive CHB infections. The treatment regimens and associated costs being modeled are based on clinical practice in Ontario. In previously published decision-analytic models from other countries, some included ADV as an alternative strategy. This, however, was not considered in our study because its use is not common in Canada and it has been moved to second-line oral antiviral medication according to the most recent AASLD guideline. We therefore included ADV only as a rescue therapy for certain resistance patients. Also, we used a more systematic way to identify the clinical trials and conducted meta-analyses to derive the parameter inputs rather than relying on one single trial. Although the differences in time horizon, perspective, discount rate, patient population, modeling assumptions, and treatment regimen make the comparison of cost and effectiveness estimates over time difficult, the life expectancy predicted by the model corresponded closely to other published evaluations when using the same discount rate. We were also able to compare the projected 10-year cumulative incidence of cirrhosis and HCC with the results from two other published economic evaluations [61, 67] that reported this data. Figure 6 shows the comparisons. Spackman and Veenstra's study [61] assumed a fixed 4-year antiviral treatment in the model and a reduced risk of cirrhosis and HCC applied only for the first year of treatment. Yuan et al.'s model [67] assumed only a 1-year treatment of ETV versus LAM. Overall, the projected cumulative incidence is lower in the present model since the treatments were assumed to reduce the risk of cirrhosis and HCC for 5 years. Despite the differences between studies, the cost-effectiveness results of our study are highly consistent with previously published economic evaluations. For example, modeling studies from the United Kingdom [6] and Spain [68] demonstrated that first-line use of TDF is more effective and less costly than first-line use of ETV, ADV, and LAM. Earlier studies also showed that ETV dominated LdT when TDF was still not available in their local settings. There are some limitations of this study. For chronic HBV infection, the outcomes of most interest for policy decision making are life-years and QALYs, while the measures in clinical trials are surrogate outcomes obtained at short-term follow-up (mostly 1 year). To extrapolate clinical trial results, especially the risk of cirrhosis and HCC, better prediction tools should be examined by further research. So far, observational studies on the long-term risk assessment for HCC and cirrhosis under newer NAs are not available in the literature, and current risk prediction tools were not developed for on-treatment risk assessments. In addition, because of the lack of long-term observational data, it is impossible to further validate the model and calibrate model estimates against empirical data. We hope that future research can provide such information for CHB-related complications, especially cirrhosis, decompensated cirrhosis, and HCC. Furthermore, the use of time-dependent transition probabilities may be explored in future economic evaluations, since age has been demonstrated to significantly affect the incidence of CHB-related complications. A comparison of the use of constant probabilities versus time-dependent probabilities in modeling examined by Sun and Faunce [69] found that there was a 10% difference in mortality rates when using different transition probabilities from HBeAg-positive CHB to cirrhosis over 40 years. HRQOL data used in this analysis were generally slightly lower than those used in previously published economic evaluations. This explains why the expected QALYs were slightly lower than in other studies. A potential concern is that the utility of CHB from Levy et al.'s study is lower than that of compensated cirrhosis, which might have been influenced by the descriptions of the diseases presented to the interview respondents. Other published CHB-related health utility studies also have the same issue. Given the results of our extensive sensitivity analyses, however, we do not think that this affects the cost-effectiveness status of the treatment options. There are potential concerns regarding the generalizability of the study results. We suspect that the ICERs may vary by patient characteristics, because age, sex, baseline HBV DNA level, serum ALT level, family history of cirrhosis, alcohol consumption, and smoking are all established confounding factors of long-term CHB-related disease progression. The chosen patient population in our model is based on the clinical trials in which key disease transition probabilities were derived. It could be that patients with certain risk factors or coinfections may benefit more or less from the treatments under evaluation, but this information is not available at this time. Whether any treatment option is clearly better on costs, utility, or both is uncertain and that was the primary reason for conducting the cost-utility model. Similarly, the cost-effectiveness and dominance of any treatment in patient subgroups is uncertain due to the lack of clinical effectiveness data in patient subgroups. Also, this study focused on HBeAg-positive populations, because more complex treatment regimens are used for HBeAg-negative patients, and modifications to the model structure and clinical effectiveness data will be required. Future research is needed to evaluate the cost-effectiveness of NAs for certain patient subgroups and HBeAg-negative CHB infections.
Conclusion
Results from the present analysis showed that for the specified patient cohort with HBeAg-positive chronic HBV infection, antiviral treatment with TDF appeared to be highly cost-effective and the optimal strategy among NA monotherapies. Probabilistic sensitivity analysis demonstrated the robustness of the results. When WTP thresholds range from 0 to Can $200,000 per QALY, there was a 0.63 to 0.81 probability that TDF is the most cost-effective strategy, followed by ETV, which had a 0.13 to 0.23 probability to be the most cost-effective treatment. LAM was the optimal strategy for lower WTP thresholds (below Can $40,000 per QALY) in as much as 23% of the simulations. In addition, TDF dominated all other alternative therapies in most simulations under different model assumptions. The results are consistent with the AASLD guideline that recommended that preference be given to ETV and TDF and are also consistent with the current reimbursement conditions in Ontario, which covers TDF without restrictions, along with LAM and ETV in the Exceptional Access Program. sor Jean-Eric Tarride, and Post-Doctoral Fellow Na Guo (all affiliated to PATH Research Institute). Also, the principle investigator greatly appreciates the persistent support from James Howard and David Fieldman.
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